Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
KMTS vs FEMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KMTS Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)
KMTS Overall Winner
6-Pillar Tally: KMTS 2 – 2 FEMY (2 Tie)
Matrix Metrics: KMTS 6 – 2 FEMY
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).
- Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY).
- Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About KMTS vs FEMY
KMTS
Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
$27.97
-2.34% 1D
Market Cap
$1.7B
TTM Revenue
$107M
Forward P/E
N/M
Beta / 30D Vol
1.84β · 63% Vol
Unified Composite Score
43.8
HOLD
Tech 21.0
Fund 39.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
FEMY
Femasys Inc. Common Stock
$1.28
-9.86% 1D
Market Cap
$11.9M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
4.01β · 72% Vol
Unified Composite Score
52.6
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (KMTS 2 – 2 FEMY)
1. Valuation Multiples
FEMY
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
15.5x
4.9x
2. Growth & Scale
KMTS
Revenue Growth (YoY)
+59.9%
-18.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$107M
$2.3M
Market Cap
$1.7B
$11.9M
3. Profitability & Quality
KMTS
Gross Margin
53.9%
60.9%
Operating Margin
-134.5%
-763.9%
Net Profit Margin
-140.4%
0.0%
Return on Equity (ROE)
-73.7%
-425.0%
4. Balance Sheet & Cash Flow
FEMY
Cash Generation (TTM)
-$117M
-$19M
Cash Flow Margin
-109.7%
N/A
Net Cash / Leverage
$53M Net Cash
-$658,045 Net Debt (0.65x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: KMTS (6) vs FEMY (2)| Institutional Metric | KMTS | FEMY | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.7B | $11.9M | KMTS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +59.9% | -18.9% | KMTS | |
| Operating Margin (TTM) | -134.5% | -763.9% | KMTS | |
| Net Profit Margin | -140.4% | 0.0% | FEMY | |
| Return on Equity (ROE) | -73.7% | -425.0% | KMTS | |
| 52-Week Range Position | 73% ($17–$32) | 17% ($0–$6) | KMTS | |
| Beta / 30D Volatility | 1.84β · 63% Vol | 4.01β · 72% Vol | KMTS | |
| Unified Institutional Score | 43.8 / 100 (HOLD) | 52.6 / 100 (HOLD) | FEMY | |
| Trailing 12M Revenue (USD) | $107M | $2.3M | Scale | |
| Gross Profit Margin (TTM) | 53.9% | 60.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 15.5x EV/Rev | N/M PEG · 4.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$117M ($53M Net Cash) | -$19M (-$658,045 Net Debt (0.65x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
KMTS +25.1 pp
3M Horizon
KMTS +41.96 pp
6M Horizon
FEMY +210.03 pp
1Y Horizon
FEMY +42.5 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | KMTS Revenue | FEMY Revenue | KMTS Op. Margin | FEMY Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -668.0% | FEMY |
| FY2021 | N/A | $0M | N/A | -706.7% | FEMY |
| FY2022 | N/A | $0M | N/A | -961.7% | FEMY |
| FY2023 | N/A | $0M | N/A | -1353.4% | FEMY |
| FY2024 | $30M | $0M | -305.8% | -1091.8% | KMTS |
| FY2025 | $60M | $0M | -177.8% | -767.0% | KMTS |
| FY2026 | $100M | N/A | -141.6% | N/A | KMTS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
KMTS
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FEMY
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
KMTS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
FEMY Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ KMTS vs FEMY Key Questions & Quantitative Answers
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY). Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KMTS leads the Growth & Scale pillar: KMTS posts +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), KMTS cumulative revenue shifted +233.3% while FEMY shifted N/A. In operating R&D and SG&A reinvestment, KMTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.
FEMY screens cheaper on headline valuation multiples. KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KMTS (-73.7% ROE) versus FEMY (-425.0% ROE) capital efficiency.
In options market volatility and institutional positioning, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FEMY vs KMTS · Reverse Pair
KMTS vs BBNX
· Sector Peer
KMTS vs CBLL
· Sector Peer
KMTS vs HTFL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking